Vaxxinity has joined TransCelerate BioPharma as the first emerging biotechnology organization of the trailblazing consortium that is accelerating and simplifying the research and development of innovative new therapies.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VAXX:
- Vaxxinity Joins TransCelerate Research and Development Consortium
- Vaxxinity announces first subjects dosed in Phase 1 trial of VXX-401
- Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
- Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
- Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida